COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：4
|
作者：
Furneri, G. [1 ]
Santoni, L. [2 ]
Ricella, C. [2 ]
Prosperini, L. [3 ]
机构：
[1] EBMA Consulting, Melegnano, Italy
[2] Biogen, Milan, Italy
[3] Sapienza Univ, Dept Neurol & Psychiat 3, Rome, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2588
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM71
引用
收藏
页码：A695 / A695
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence
    Graham, J. B.
    Earnshaw, S. R.
    Castelli-Haley, J.
    Oleen-Burkey, M.
    Johnson, K. P.
    VALUE IN HEALTH, 2007, 10 (06) : A381 - A381
  • [32] COST-EFFECTIVENESS ANALYSIS OF OFATUMUMAB FOR RELAPSING REMITTING MULTIPLE SCLEROSIS TREATMENT IN ITALY
    Antonazzo, I. C.
    Nica, M.
    Cortesi, P.
    Ritrovato, D.
    Mantovani, L. G.
    VALUE IN HEALTH, 2022, 25 (12) : S342 - S343
  • [33] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [34] COST-EFFECTIVENESS ANALYSIS OF DACLIZUMAB BETA IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN ITALY
    Demma, R.
    Casamassima, G.
    Cocco, E.
    Di Turi, R.
    Paolicelli, D.
    Fantaccini, S.
    Santoni, L.
    Fumeri, G.
    VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [35] Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Santoni, Laura
    Marchesi, Chiara
    Iannazzo, Sergio
    Cortesi, Paolo Angelo
    Piacentini, Patrizio
    Caputi, Achille Patrizio
    Mantovani, Lorenzo Giovanni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (02) : 67 - 80
  • [36] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Fumeri, G.
    Santoni, L.
    Marchesi, C.
    Iannazzo, S.
    Cortesi, R.
    Piacentini, P.
    Caputi, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2015, 18 (07) : A697 - A697
  • [37] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [38] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [39] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [40] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
12345